SUPN
Supernus Pharmaceuticals Inc
NASDAQ · Pharmaceuticals
$51.65
+2.28 (+4.62%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 678.15M | 648.88M | 1.08B | 1.12B | 1.08B |
| Net Income | 75.69M | 65.18M | 226.99M | 218.96M | 223.93M |
| EPS | — | — | — | — | — |
| Profit Margin | 11.2% | 10.6% | 20.9% | 19.5% | 20.7% |
| Rev Growth | +4.5% | +4.5% | +13.5% | +10.9% | -8.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 1.03B | 863.19M | 832.43M |
| Total Equity | — | — | 1.99B | 1.94B | 2.13B |
| D/E Ratio | — | — | 0.52 | 0.45 | 0.39 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 163.58M | 148.70M | 332.85M | 345.29M | 368.42M |
| Free Cash Flow | — | — | 190.42M | 147.80M | 181.78M |